_2020091018165303jzv.jpg "Decoding The World Of ETF")
My Account
Associate Partners:
Associate Partners:
Cipla share price fell over 5 percent in the early trade on February 26 after the company received a warning letter from the USFDA.
The company has received a warning letter from the United States Food and Drug Administration (USFDA) for the company's Goa manufacturing facility.
The inspection conducted from 16-27 September 2019.
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.
At 09:18 hrs Cipla was quoting at Rs 414.05, down Rs 11.30, or 2.66 percent on the BSE.
The share touched its 52-week high Rs 585.50 and 52-week low Rs 389.55 on 27 May, 2019 and 11 October, 2019, respectively.
Currently, it is trading 29.28 percent below its 52-week high and 6.29 percent above its 52-week low.
Explained | Sensex hits 50k milestone: Here is what led to the rally Watch more 
Ideas For Profit | Indigo Paints IPO: Will it colour your portfolio green? Watch more 
Digital Trends: TikTok’s growing popularity despite the ban to emergence of Netflix as ‘threat’ to other streaming platforms in India and more Watch more 
Watch: Ravi Shastri dressing room speech at Gabba after India victory Watch more 
